Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

1.

The contrasting roles of PPARδ and PPARγ in regulating the metabolic switch between oxidation and storage of fats in white adipose tissue.

Roberts LD, Murray AJ, Menassa D, Ashmore T, Nicholls AW, Griffin JL.

Genome Biol. 2011 Aug 11;12(8):R75. doi: 10.1186/gb-2011-12-8-r75.

PMID:
21843327
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.

Evans JL, Lin JJ, Goldfine ID.

Curr Diabetes Rev. 2005 Aug;1(3):299-307. Review.

PMID:
18220606
[PubMed - indexed for MEDLINE]
3.

Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.

Luquet S, Lopez-Soriano J, Holst D, Gaudel C, Jehl-Pietri C, Fredenrich A, Grimaldi PA.

Biochimie. 2004 Nov;86(11):833-7. Review.

PMID:
15589693
[PubMed - indexed for MEDLINE]
4.

Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes.

Luquet S, Gaudel C, Holst D, Lopez-Soriano J, Jehl-Pietri C, Fredenrich A, Grimaldi PA.

Biochim Biophys Acta. 2005 May 30;1740(2):313-7. Epub 2004 Dec 8. Review.

PMID:
15949697
[PubMed - indexed for MEDLINE]
Free Article
5.

Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome.

Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15924-9. Epub 2003 Dec 15.

PMID:
14676330
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.

Eur J Pharmacol. 2008 Apr 14;584(1):192-201. doi: 10.1016/j.ejphar.2007.12.036. Epub 2008 Feb 14.

PMID:
18346728
[PubMed - indexed for MEDLINE]
7.

Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects.

Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanen M, Ventre J, Wu MS, Berger GD, Mosley R, Marquis R, Santini C, Sahoo SP, Tolman RL, Smith RG, Moller DE.

J Biol Chem. 1999 Mar 5;274(10):6718-25.

PMID:
10037770
[PubMed - indexed for MEDLINE]
Free Article
8.

Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.

Keil S, Matter H, Schönafinger K, Glien M, Mathieu M, Marquette JP, Michot N, Haag-Diergarten S, Urmann M, Wendler W.

ChemMedChem. 2011 Apr 4;6(4):633-53. doi: 10.1002/cmdc.201100047. Epub 2011 Mar 11.

PMID:
21400663
[PubMed - indexed for MEDLINE]
9.

Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes.

Serrano-Marco L, Rodríguez-Calvo R, El Kochairi I, Palomer X, Michalik L, Wahli W, Vázquez-Carrera M.

Diabetes. 2011 Jul;60(7):1990-9. doi: 10.2337/db10-0704. Epub 2011 May 26.

PMID:
21617181
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome.

Takahashi S, Tanaka T, Kodama T, Sakai J.

Pharmacol Res. 2006 Jun;53(6):501-7. Epub 2006 Mar 29. Review.

PMID:
16713711
[PubMed - indexed for MEDLINE]
11.

Expression of peroxisome proliferator-activated receptor PPARdelta promotes induction of PPARgamma and adipocyte differentiation in 3T3C2 fibroblasts.

Bastie C, Holst D, Gaillard D, Jehl-Pietri C, Grimaldi PA.

J Biol Chem. 1999 Jul 30;274(31):21920-5.

PMID:
10419513
[PubMed - indexed for MEDLINE]
Free Article
12.

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.

Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, Biswas C, Parikh M, Sharma N, Tanen MR, Thompson GM, Ventre J, Adams AD, Mosley R, Surwit RS, Moller DE.

Mol Endocrinol. 2003 Apr;17(4):662-76. Epub 2003 Jan 16.

PMID:
12554792
[PubMed - indexed for MEDLINE]
13.

A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.

Jeong HW, Lee JW, Kim WS, Choe SS, Shin HJ, Lee GY, Shin D, Lee JH, Choi EB, Lee HK, Yon GH, Cho B, Kim HR, Choi SH, Chung YS, Park SB, Chung H, Ro S, Kim JB.

Mol Pharmacol. 2010 Nov;78(5):877-85. doi: 10.1124/mol.110.065748. Epub 2010 Aug 19.

PMID:
20724462
[PubMed - indexed for MEDLINE]
Free Article
14.

Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.

Coll T, Alvarez-Guardia D, Barroso E, Gómez-Foix AM, Palomer X, Laguna JC, Vázquez-Carrera M.

Endocrinology. 2010 Apr;151(4):1560-9. doi: 10.1210/en.2009-1211. Epub 2010 Feb 25.

PMID:
20185762
[PubMed - indexed for MEDLINE]
15.

PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.

Kim MK, Chae YN, Choi SH, Moon HS, Son MH, Bae MH, Choi HH, Hur Y, Kim E, Park YH, Park CS, Kim JG, Lim JI, Shin CY.

Eur J Pharmacol. 2011 Jan 15;650(2-3):673-81. doi: 10.1016/j.ejphar.2010.10.044. Epub 2010 Oct 23.

PMID:
20974124
[PubMed - indexed for MEDLINE]
16.

Involvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of peroxisome proliferator-activated receptor gamma activation in mice.

Guo X, Xu K, Zhang J, Li H, Zhang W, Wang H, Lange AJ, Chen YE, Huo Y, Wu C.

J Biol Chem. 2010 Jul 30;285(31):23711-20. doi: 10.1074/jbc.M110.123174. Epub 2010 May 24.

PMID:
20498376
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Multi-tissue, selective PPARγ modulation of insulin sensitivity and metabolic pathways in obese rats.

Hsiao G, Chapman J, Ofrecio JM, Wilkes J, Resnik JL, Thapar D, Subramaniam S, Sears DD.

Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E164-74. doi: 10.1152/ajpendo.00219.2010. Epub 2010 Oct 19.

PMID:
20959535
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity.

Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM.

Cell. 2003 Apr 18;113(2):159-70.

PMID:
12705865
[PubMed - indexed for MEDLINE]
Free Article
19.

Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study.

Jucker BM, Yang D, Casey WM, Olzinski AR, Williams C, Lenhard SC, Legos JJ, Hawk CT, Sarkar SK, Newsholme SJ.

Am J Physiol Endocrinol Metab. 2007 Nov;293(5):E1256-64. Epub 2007 Aug 28.

PMID:
17726146
[PubMed - indexed for MEDLINE]
Free Article
20.

Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.

Hiuge-Shimizu A, Maeda N, Hirata A, Nakatsuji H, Nakamura K, Okuno A, Kihara S, Funahashi T, Shimomura I.

Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):792-9. doi: 10.1161/ATVBAHA.110.221747. Epub 2011 Jan 13.

PMID:
21233451
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk